Review of dose–response curves for acute antimigraine drugs: triptans, 5-HT_1F agonists and CGRP antagonists

Bibliography

• Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain 2013;14:1
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163–96
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343–9
   PubMed Web of Science ®Google Scholar
• Saxena PR, Tfelt-Hansen P. The Headaches. In: Olesen J, Goadsby PJ, Ramadan NM, et al. Editors 3rd edition. Triptans, 5HT1B/1D agonists in the acute treatment ofbmigraine. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 469–503
   Google Scholar
• Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254:705–12
   PubMed Web of Science ®Google Scholar
• Diener H-C, Lampl C, Reimnitz P, et al. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006;6:563–73
   PubMedGoogle Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259–87
   PubMed Web of Science ®Google Scholar
• Diener HC. Headache: insight, understanding, treatment and patient management. Int J Clin Pract Suppl 2013(178):33–6
   PubMedGoogle Scholar
• Tfelt-Hansen P, Seidelin K, Stepanavage M, et al. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. Br J Clin Pharmacol 2002;54:38–44
   PubMed Web of Science ®Google Scholar
• de Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000;68:418–26
   PubMed Web of Science ®Google Scholar
• Maassen van den Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98(1):25–30
   PubMed Web of Science ®Google Scholar
• Welch KM. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience. Cephalalgia 2001;21(Suppl 1):25–8
   PubMedGoogle Scholar
• Dodick D, Martin V, Smith T, et al. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004;44(Suppl 1):S20–30
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271–5
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. Neurotherapeutics 2010;7:164–75
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807–18
   PubMed Web of Science ®Google Scholar
• Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010;24:539–48
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs 2009;10:711–20
   PubMed Web of Science ®Google Scholar
• Visser WH, Ferrari MD, Bayliss EM, et al. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia 1992;12:308–13
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials. Cephalalgia 1993;13:238–44
   PubMed Web of Science ®Google Scholar
• Cady R, Wendt J, Kirchner J. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831–5
   PubMed Web of Science ®Google Scholar
• The Subcutaneus Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325(5):316–21
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014;5:CD009108
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet 2001;358(9294):1668–75
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Hogenhuis L, Olesen J. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998;5:469–77
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. Cephalalgia 2008;28(7):767–8
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633–58
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998;38(3):184–90
   PubMed Web of Science ®Google Scholar
• The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan--an oral dose-defining study. Eur Neurol 1991;31:300–5
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210–18
   PubMed Web of Science ®Google Scholar
• Havanka H, Dahlöf C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000;22:970–80
   PubMed Web of Science ®Google Scholar
• Salonen R. The triptans: novel drugs for migraine. In: Humphrey PP, Ferrari MD, Olesen J, Editors Naratriptan: the gentle triptan. Oxford: Oxford University Press; 2001. p. 228–35
   Google Scholar
• Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997;17:647–51
   PubMed Web of Science ®Google Scholar
• Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 1996;53:1132–7
   PubMed Web of Science ®Google Scholar
• The electronic Medicines Compendium (eMC) [Internet]. Available from: https://www.medicines.org.uk/emc/medicine/25568. [Last accessed 1 September 2014]
   Google Scholar
• Stark R, Dahlöf C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002;22:23–32
   PubMed Web of Science ®Google Scholar
• Sheftell F, Ryan R, Pitman V, et al. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003;43:202–13
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57(10):1811–17
   PubMed Web of Science ®Google Scholar
• Rapoport A, Ryan R, Goldstein J, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002;42(Suppl 2):S74–83
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia 2010;30:1170–8
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Diener H-C, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405–13
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener H-C, Husstedt IW, et al. Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350(11):1104–10
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70(16):1304–12
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115–23
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73(12):970–7
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlöf CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30:1443–57
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 2010;51:118–23
   PubMed Web of Science ®Google Scholar
• Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 2011;51:73–84
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011;31:712–22
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 2011;31(5):573–84
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014;34:114–25
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42(Suppl 1):3–9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 2012;26(5):375–82
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. The efficacy of transdermal sumatriptan is too low for general use in migraine. Headache 2013;53:842–3
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Pihl T, Hougaard A, et al. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 2013;2:1–11
   Google Scholar
• Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: A guide for investigators. 3rd edition. Cephalalgia; 2012. p. 6–38
   Google Scholar
• Hougaard A, Tfelt-Hansen P. Are the current IHS guidelines for migraine drug trials being followed? J Headache Pain 2010;11:457–68
   PubMed Web of Science ®Google Scholar
• Wienecke T, Olesen J, Oturai P, et al. Prostaglandin E 2(PGE 2) induces headache in healthy subjects. Cephalalgia 2009;29:509–19
   PubMed Web of Science ®Google Scholar
• Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain 2011;12:551–9
   PubMed Web of Science ®Google Scholar
• Ploug KB, Baun M, Hay-Schmidt A, et al. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol 2010;637(1-3):109–17
   PubMed Web of Science ®Google Scholar
• Anttila V, Stefansson H, Kallela M, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42:869–73
   PubMed Web of Science ®Google Scholar